The Homocystinuria drugs in development market research report provides comprehensive information on the therapeutics under development for Homocystinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Homocystinuria. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Homocystinuria and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Homocystinuria by eight companies/universities/institutes. The top development phase for Homocystinuria is discovery with three drugs in that stage. The Homocystinuria pipeline has eight drugs in development by companies and one by universities/ institutes. Some of the companies in the Homocystinuria pipeline products market are: Syntis Bio, Travere Therapeutics and University of Colorado Denver.
The key targets in the Homocystinuria pipeline products market include Cystathionine Beta Synthase, and Enteropeptidase.
The key mechanisms of action in the Homocystinuria pipeline product include Cystathionine Beta Synthase Replacement with one drug in Phase III. The Homocystinuria pipeline products include two routes of administration with the top ROA being Oral and five key molecule types in the Homocystinuria pipeline products market including Gene Therapy, and Recombinant Enzyme.
Homocystinuria overview
Homocystinuria refers to a group of inherited disorders where the body is unable to process certain building blocks of proteins (amino acids) properly. This leads to increased amounts of homocysteine and other amnio acids in the blood and urine. This is caused by cystathionine β-synthase (CBS) deficiency is characterized by involvement of the eye (ectopia lentis and/or severe myopia), skeletal system, vascular system, and CNS.
For a complete picture of Homocystinuria’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
